Paper28875498
Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype.
Kagami T and 10 others. Clin Pharmacol Ther, 2018. Cited by 31 papers, by iCite.
Cite this record
ConductScience Library. Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype. Papers, record 28875498. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28875498
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Comparative Study of Effects of Vonoprazan and Esomeprazole on Antiplatelet Function of Clopidogrel or Prasugrel in Relation to CYP2C19 Genotype.
- PubMed
Topics17
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Blood Platelets | Major topic |
| Clopidogrel | Major topic |
| Cytochrome P-450 CYP2C19 | Major topic |
| Esomeprazole | Major topic |
| Platelet Aggregation Inhibitors | Major topic |
| Prasugrel Hydrochloride | Major topic |
| Pyrroles | Major topic |
| Sulfonamides | Major topic |
| Adult | |
| Asian People | |
| Drug Interactions | |
| Female | |
| Genotype | |
| Humans | |
| Male | |
| Platelet Aggregation | |
| Young Adult |
Source PubMed
Comments and corrections2
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers | Source |
|---|---|---|---|---|
| Comment in | 29603200 | CYP-Mediated Drug-Drug Interaction Is Not a Major Determinant of Attenuation of Antiplatelet Function of Clopidogrel by Vonoprazan. | https://conductscience.org/library/papers/29603200 | PubMed |
| Comment in | 29663346 | Response to "CYP-Mediated Drug-Drug Interaction Is Not a Major Determinant of Attenuation of Antiplatelet Function of Clopidogrel by Vonoprazan". | https://conductscience.org/library/papers/29663346 | PubMed |
Cited by24
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 31 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42646320 | In Vivo Metabolite Formation and In Vitro Cytochrome P450-Mediated Metabolism of Vonoprazan in Horses. | Metabolites | 2026 | https://conductscience.org/library/papers/42646320 | PubMed |
| 42427013 | Effect of Low-Dose Vonoprazan on Hepatic Cytochrome P450 Activity By 13C-Aminopyrine Breath Test in Healthy Subjects. | Med Sci Monit | 2026 | https://conductscience.org/library/papers/42427013 | PubMed |
| 42316519 | Management of Peptic Ulcer Disease in Patients Taking Antithrombotic Agents. | Korean J Helicobacter Up Gastrointest Res | 2026 | https://conductscience.org/library/papers/42316519 | PubMed |
| 42220767 | Vonoprazan vs Proton Pump Inhibitors for Gastroprotection in Anticoagulated Patients: A Real-World Cohort Study. | Cureus | 2026 | https://conductscience.org/library/papers/42220767 | PubMed |
| 41368631 | Recent advances in gut microbiota metabolite regulation of hepatic pregnane X receptor. | Front Immunol | 2025 | https://conductscience.org/library/papers/41368631 | PubMed |
| 40117040 | Comparative effectiveness of potassium-competitive acid blockers and proton pump inhibitors in dual antiplatelet therapy patients: a nationwide cohort study. | Int J Clin Pharm | 2025 | https://conductscience.org/library/papers/40117040 | PubMed |
| 39145848 | Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments. | Curr Gastroenterol Rep | 2024 | https://conductscience.org/library/papers/39145848 | PubMed |
| 38751605 | P-CAB versus PPI in the eradication of Helicobacter pylori: a systematic review and network meta-analysis. | Ther Adv Gastroenterol | 2024 | https://conductscience.org/library/papers/38751605 | PubMed |
| 37176551 | Expectations for the Dual Therapy with Vonoprazan and Amoxicillin for the Eradication of H. pylori. | J Clin Med | 2023 | https://conductscience.org/library/papers/37176551 | PubMed |
| 36897544 | Evaluation of CYP2C19-Mediated Pharmacokinetic Drug Interaction of Tegoprazan, Compared with Vonoprazan or Esomeprazole. | Clin Pharmacokinet | 2023 | https://conductscience.org/library/papers/36897544 | PubMed |
| 35445847 | Influence of daily versus alternate-day dosing of vonoprazan on intragastric pH, serum gastrin, and the antiplatelet function of clopidogrel : Influence of alternate-day dosing of vonoprazan. | Eur J Clin Pharmacol | 2022 | https://conductscience.org/library/papers/35445847 | PubMed |
| 35146797 | Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole. | Br J Clin Pharmacol | 2022 | https://conductscience.org/library/papers/35146797 | PubMed |
| 34867368 | Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects. | Front Pharmacol | 2021 | https://conductscience.org/library/papers/34867368 | PubMed |
| 33774763 | Risk of major adverse cardiovascular events for concomitant use of clopidogrel and proton pump inhibitors in patients inheriting CYP2C19 loss-of-function alleles: meta-analysis. | Int J Clin Pharm | 2021 | https://conductscience.org/library/papers/33774763 | PubMed |
| 33693287 | Effects of Vonoprazan on the Antiplatelet Function of Prasugrel Assessed by the VerifyNow P2Y12 Assay in Patients With Coronary Artery Disease. | Circ Rep | 2020 | https://conductscience.org/library/papers/33693287 | PubMed |
| 33575950 | Pharmacokinetics and Pharmacodynamics of Esomeprazole/Sodium Bicarbonate Immediate-Release Capsules in Healthy Chinese Volunteers: A Cross-Over, Randomized Controlled Trial. | Adv Ther | 2021 | https://conductscience.org/library/papers/33575950 | PubMed |
| 32581516 | Effects of Voriconazole on the Pharmacokinetics of Vonoprazan in Rats. | Drug Des Devel Ther | 2020 | https://conductscience.org/library/papers/32581516 | PubMed |
| 32116727 | Cytochrome P450-Based Drug-Drug Interactions of Vonoprazan In Vitro and In Vivo. | Front Pharmacol | 2020 | https://conductscience.org/library/papers/32116727 | PubMed |
| 31267433 | Different Clopidogrel Response Elicited by Lansoprazole or Esomeprazole in Patients Undergoing Neurointervention with Dual Antiplatelet Therapy. | Clin Drug Investig | 2019 | https://conductscience.org/library/papers/31267433 | PubMed |
| 30993551 | Inhibitory Effect of Vonoprazan on the Metabolism of [14C]Prasugrel in Human Liver Microsomes. | Eur J Drug Metab Pharmacokinet | 2019 | https://conductscience.org/library/papers/30993551 | PubMed |
Genes3
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| CYP2C19 | 1557 | PubTator's text mining | https://conductscience.org/library/genes/1557 | NCBI Gene |
| CYP3A4 | 1576 | PubTator's text mining | https://conductscience.org/library/genes/1576 | NCBI Gene |
| P2RY12 | 64805 | PubTator's text mining | https://conductscience.org/library/genes/64805 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28875498
GET https://conductscience.org/api/papers/v1/28875498/cited_by?page=2